ResMed’s Astral Life Support Ventilator Now Has AutoEPAP in U.S.
ResMed (NYSE: RMD) (ASX: RMD), a global leader in cloud-connected respiratory care devices, today announced key upgrades to its Astral life support ventilators, including Optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180827005110/en/
ResMed's Astral ventilator (Photo: Business Wire)
What is AutoEPAP?
AutoEPAP (automatic expiratory positive airway pressure) automatically adjusts a patient’s expiratory pressure in response to flow limitations or obstruction of the upper airway.
AutoEPAP is now available in the United States, and already in use in other markets. It’s an option when in Astral’s iVAPS (intelligent Volume-Assured Pressure Support) mode that automatically adapts to a patient’s changing pressure needs as their respiratory disease progresses.
In addition to AutoEPAP, Astral users worldwide can now:
- Easily change interfaces: Patients can easily change between a mouthpiece and a full face, nasal or pillows mask from a single limb circuit.
- Customize program names: Clinicians can now name programs on a patient’s Astral device for fast, easy access.
“These significant upgrades make Astral one of the most advanced life support ventilators on the market,” said Richie McHale, president of ResMed’s Respiratory Care business. “It’s already proven to stabilize ventilation in significantly fewer breaths than its leading competitor,1 and today’s innovations offer greater ease of use and even more peace of mind to patients across a wide range of respiratory diseases than ever before.”
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
1 Diesem Ryan. Astral/Trilogy iVAPS/AVAPS Comparison. Valley Inspired Products 2016; 16011.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Jam City Announces $145 Million in Strategic Financing to Fuel Consolidation and Growth Initiatives16.1.2019 13:00 | Pressemelding
Jam City, Inc., a leader in mobile entertainment, today announced $145 million in strategic financing jointly led by JPMorgan Chase Bank, N.A. and Bank of America Merrill Lynch, and a syndicate of lenders including Silicon Valley Bank, SunTrust Bank and CIT Bank, N.A. The financing will support Jam City’s acquisitions and global growth initiatives. Today’s announcement follows Jam City’s recent multi-year game development deal with Disney and expansion to Toronto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005007/en/ Chris DeWolfe, Jam City CEO, and Josh Yguado, Jam City COO and President (left to right). Photo credit: Ethan Pines “In a global mobile games market that is consolidating, Jam City could not be more proud to be working with JPMorgan, Bank of America Merrill Lynch, Silicon Valley Bank, SunTrust Bank and CIT Bank to strategically support the financing of our acquisition and growth plans,” said Chris DeWo
VITEC Streamlines IPTV, Digital Signage, and Video Wall Workflows at ISE 201916.1.2019 13:00 | Pressemelding
VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced it will showcase the latest capabilities for its award-winning EZ TV IPTV & Digital Signage Platform at ISE 2019 on Stand 14-M200. The chosen solution for sports and entertainment venues, enterprise, government, and military agencies in Europe and the U.S., EZ TV’s comprehensive feature set enables any organization to centrally manage and stream HD, low-latency, in-house feeds and TV channels, as well as create eye-catching digital signage and video walls for distribution to any displays through a facility. VITEC’s EZ TV IPTV & Digital Signage Platform is ideal for the ever-changing video, marketing, and sales requirements of today's sports venues as well as for the secure dissemination and content management of full-motion video streams and offline files for enterprise and mission-critical applications and government agencies. Designed to integrate seamlessly with any IT environment and run o
Scientist.com Hosts Webinar Exploring Global Strategies for Sourcing of Real World Evidence (RWE) and Health Economics and Outcomes Research (HEOR)16.1.2019 12:55 | Pressemelding
Scientist.com, the life science industry’s leading online marketplace for outsourced research services, announced today that it has assembled a panel of industry experts to discuss best practices and global strategies when sourcing HEOR and RWE services. Set for January 24, 2019, at 12:00pm EDT, the webinar will focus on how the industry currently defines RWE and HEOR, some of the major challenges research organizations face when sourcing RWE and HEOR and emerging global trends in the strategy and regulation of RWE (including HEOR, epidemiology, market access and other RWE). “I am excited to serve on such a distinguished panel focusing on the practical uses of real world data,” said Patti Peeples, RPh, PhD, CEO and Founder, HealthEconomics.com, and Principal Researcher, HE Institute. “Many research organizations are looking to maximize this data to optimize market access while informing value-focused healthcare decisions and reducing research costs.” The panel consists of experts in RW
Bank of America Reports Fourth-Quarter 2018 Financial Results16.1.2019 11:45 | Pressemelding
Bank of America reported its fourth-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005355/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international). The conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference call and
Eurosport Signs an Exclusive Multi-Year Partnership Deal with Outbrain, Which Includes Outbrain’s Smartfeed and Video Technology16.1.2019 11:00 | Pressemelding
Outbrain, the world’s leading native advertising platform, announced today it has signed a pan-regional deal with Eurosport, the number one destination for sports fans. The agreement spans 13 markets globally, including the UK, France, Germany, Italy, Spain, Asia, and Australia, and will be powered by Outbrain’s innovative Smartfeed technology. Smartfeed provides a content discovery feed that allows publishers to customise the user experience, improving both engagement and revenue. It is designed for a range of content from promoted articles to editorial pieces to videos, and functions across all devices including desktop, mobile, and apps. Eurosport will also utilise Outbrain’s Amplify platform to promote their own videos. Earlier this year, Outbrain released Focus, a click-to-watch video experience built for engagement and performance, and tailored for high quality and long form video content. Focus consistently results in higher click-through and completion rates, which makes it ide
Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases16.1.2019 11:00 | Pressemelding
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet need, today announced the expansion of its research collaboration with Cincinnati Children’s Hospital Medical Center to further elucidate the eosinophil-depleting mechanism of action of Knopp’s lead investigational drug, dexpramipexole. Eosinophils are white-blood cells that play a central role in several debilitating conditions, including asthma, hypereosinophilic syndrome (HES), and other inflammatory diseases. Dexpramipexole has been shown to selectively reduce eosinophil levels in multiple clinical trials, including a Phase 2 study in HES and a Phase 2 trial in chronic rhinosinusitis with nasal polyps. Knopp is advancing dexpramipexole into Phase 2 development in severe asthma and Phase 3 development in HES. The research at Cincinnati Children’s Hospital Medical Center is being led by Patricia C. Fu